Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Add like
Add dislike
Add to saved papers

Incidence and treatment of neoplasia after transplantation.

Cancer incidence in patients who undergo transplantation ranges from 4% to 18% (average, 6%). We have data on 7248 types of malignancy that developed in 6798 patients. The predominant tumors are lymphomas, skin and lip carcinomas, vulvar or perineal carcinomas, in situ uterine cervical carcinomas, and Kaposi's sarcoma. Tumors appear relatively early after transplantation. The earliest are Kaposi's sarcomas, which appear an average of 22 months after transplantation, whereas the latest are tumors that involve the vulva and perineum, which appear an average of 113 months after transplantation. Unusual features of the lymphomas include a high incidence of non-Hodgkin's lymphomas, frequent involvement of extranodal sites, marked predilection for the brain, and frequent allograft involvement by tumor. Lymphomas are much more common in heart or heart and lung recipients than in kidney recipients, and in pediatric patients compared with adults. Neoplastic regression after reduction or cessation of immunosuppressive therapy occurs in some patients with non-Hodgkin's lymphoma or Kaposi's sarcoma.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app